Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

Overall, HIT 3 earned an estimated 72.03 crore net at the Indian box office in 11 days. From here, the film will cover some distance, but entering the 100 crore club looks impossible now.

For more stories and updates, stay tuned to Koimoi. Must Read: Jaat Box Office Day 32: With 666% More Earnings Than Sikandar Already, Sunny Deol Aims 13.3 Times Higher Collection On 5th Weekend!

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis ...

The regulatory filing states that enrollment in the global Phase 3 HAELO study of NTLA-2002 for hereditary angioedema is on track. The company expects to complete enrollment in the third ...

Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial ...

A Box of Toys is a radio program dedicated to the mystery of obscure music. The sheer volume of new and original artists is utterly overwhelming and A Box of Toys endeavors to pluck these voices out ...

FRANKFURT, May 26 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious ...

Samantha Ruth Prabhu's debut production, 'Subham,' a horror-comedy, has garnered Rs 3.08 crore in India net over five days, driven by positive word-of-mouth. Set in Bhimilipuram, the film follows ...

Q: What is the Day 1 Box Office Collection of Hate Story 3? A: Hate Story 3 collected ₹9.72 cr. on Day 1 at the India box office. Q: What were the opening weekend collections of Hate Story 3?

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline. California-based ...